Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amcor PLC (AMCR) vs BridgeBio Pharma Inc (BBIO) Price & Performance

BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

Amcor PLC vs BridgeBio Pharma Inc — how do they compare? Amcor PLC trades at $47.5 (market cap $21.78B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Amcor PLC is the larger of the two by market cap, and Amcor PLC pays a 5.52% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

AMCRBBIO
Market Cap
$21.78B$16.61B
Sector
Basic MaterialsHealth
52-Week High
$50.58$90.17
52-Week Low
$36.69$47.29
Enterprise Value
$36.90B$18.16B
Dividend Yield
5.52%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amcor PLC

Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.

Read more on AMCR

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO